Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.
about
Current and future alternative therapies for beta-thalassemia majorGene therapy for primary immunodeficienciesRetroviral integrations in gene therapy trialsGene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome.Wiskott-Aldrich syndrome: a comprehensive review.Gene therapy for PIDs: progress, pitfalls and prospectsComparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors.Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases.Vector integration and tumorigenesis.Gene therapy for inherited immunodeficiency.Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease.Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer.Combining stem cells and genes for effective therapeutics.Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.Multidimensional Genome-wide Analyses Show Accurate FVIII Integration by ZFN in Primary Human CellsExtended survival of glioblastoma patients after chemoprotective HSC gene therapyMature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.Development of gene therapy for blood disorders: an update.The Sleeping Beauty transposon system for clinical applications.Current progress on gene therapy for primary immunodeficiencies.Gene delivery techniques for adult stem cell-based regenerative therapy.Gene therapy for monogenic disorders of the bone marrow.Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies.BET-independent MLV-based Vectors Target Away From Promoters and Regulatory Elements.Self-inactivating MLV vectors have a reduced genotoxic profile in human epidermal keratinocytes.Practical considerations for chimeric antigen receptor design and delivery.Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy.Prospects for Foamy Viral Vector Anti-HIV Gene Therapy.
P2860
Q26750906-7B43FBAC-2642-4589-8EF0-D3BF8D0E79F4Q26864856-9DF3BF5F-7058-4FAB-9716-2B5654D137C6Q26991660-7BFF7D2E-B6D1-49BB-BA14-026FD46BC77CQ30364488-67023D9F-A5ED-410E-B2F1-6D694072356DQ33399943-222DC70B-9F33-44E4-9C60-0F3707F161E1Q33406620-49883578-B54C-43FE-9AE8-B7EF72260188Q33406944-CE596B88-DFEE-4D66-80C4-59C27891B360Q33408529-FF642B0E-959E-4C37-892C-23A427453FF7Q33552027-0F5A67D0-34B5-44E6-9E53-818791C66276Q33782783-92CFEE15-2356-4DCA-AAC9-3047C0DA6A3CQ34419791-F2D813C9-957F-4301-917D-4AF911B0AC25Q34449867-49B309F1-02B1-41FB-B316-EDE934F5B63BQ34526988-9EAC2C7F-E208-4D84-9AEE-E04D1E04B9B2Q35513622-0892A639-E149-4E7A-B181-46993937BCDDQ36659242-92CE3ED5-A7FC-453D-8724-48027C301953Q36675323-E47D1D41-ACDB-4CFE-8A46-9B739B49B8FDQ36834118-72989FA8-2647-4091-8F00-472D9C601B93Q36915132-D9B9505B-6631-455B-9E77-40DDB73EAE28Q37132611-0C5C28E2-B952-411C-AE85-609976556F3CQ37969195-14E6DE66-3EE5-4A5C-897A-481444717062Q38110363-CE256BB1-F8AC-4A04-B119-ABA28A2A6DD6Q38155214-8B01D7CE-2088-4032-97C0-F2A57AF2C153Q38516548-E097D119-A7D6-485D-9C32-E49AE70EA520Q40792533-2A1E1D3B-E7E8-4D71-BFCF-BB8F037D9B95Q42203159-3FF6FC5A-AF04-4FD8-8F0F-1313B2F57BC2Q42820688-41B3D264-C035-4F2C-8D68-2EBF99A98B17Q45868559-9AA71E28-76B0-4172-AD0D-6FE5A31EB4FBQ45872766-21EE13C0-478C-4782-A250-90DF6571500FQ50878341-641525D3-4FCA-4425-907C-E6DC88DA2284
P2860
Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Development of novel efficient ...... stem cell based gene therapy.
@en
Development of novel efficient ...... stem cell based gene therapy.
@nl
type
label
Development of novel efficient ...... stem cell based gene therapy.
@en
Development of novel efficient ...... stem cell based gene therapy.
@nl
prefLabel
Development of novel efficient ...... stem cell based gene therapy.
@en
Development of novel efficient ...... stem cell based gene therapy.
@nl
P2093
P50
P356
P1476
Development of novel efficient ...... stem cell based gene therapy.
@en
P2093
Adrian Schwarzer
Christoph Klein
Christopher Baum
Daniela Zychlinski
Elmar Jaeckel
Emanuele G Coci
Inés Avedillo Díez
Kaan Boztug
Melanie Galla
Nonsikelelo Mpofu
P304
P356
10.1021/MP200132U
P407
P577
2011-08-31T00:00:00Z